Tavapadon FDA approval and royalty commercialization

Description Tavapadon’s U.S. approval as AbbVie’s Juvmo is tied to commercialization plans and a royalty-rights acquisition by DRI Healthcare. Overview DRI Healthcare agreed to buy certain U.S. net-sales royalty participation rights in tavapadon for $316 million, subject to FDA approval. The FDA later approved AbbVie’s once-daily… Read more